Hepatitis C virus infection

Hepatitis C virus infection is a worldwide systemic disease state with consequences that reach from the liver into the kidneys, dialysis units, transplant programs, and public-health systems. Affecting an estimated 3% of the global population—more than 150 million and, in some estimates, around 170 million people—it has been associated with chronic kidney disease, glomerular lesions, serious infection, cardiovascular and liver-related death, and poorer long-term outcomes after kidney transplantation. Its decisive clinical importance lies in this combination of hidden prevalence, persistent extrahepatic injury, transmissibility in medical environments, and the changing possibility of cure.

Definition and Detection

Hepatitis C virus infection is not synonymous with a positive antibody test. Screening begins with anti-HCV antibodies, detected by third-generation enzyme-linked immunosorbent assays, but antibodies alone cannot distinguish resolved infection from ongoing disease. Chronic active infection requires both anti-HCV and detectable HCV RNA in serum, measured with sensitive molecular assays whose threshold is approximately 15 IU/ml. This distinction separates previous exposure or recovery from a continuing viral state that can damage the liver, kidneys, and other organs.

The infection was recognized after the identification of HCV as the principal cause of non-A, non-B hepatitis. The medical vocabulary therefore moved from an unnamed transfusion-associated syndrome toward a defined viral disease characterized by antibodies, RNA, genotypes, viral kinetics, and targeted drug classes. Six major genotypes and numerous subtypes have been described. Genotype 1 is globally prevalent, with subtype 1b especially common in Japan and Europe and subtype 1a in the United States; genotype 2 occurs in Mediterranean clusters, genotype 3a is frequent in the Indian subcontinent and among European intravenous drug users, genotype 4 has historical links to Egypt and Africa, and genotype 6 is mainly observed in southern China. These geographic patterns have influenced prognosis, treatment selection, and interpretation of transmission.

Distribution and Transmission

Hepatitis C virus infection remains unevenly distributed. Prevalence in Western Europe ranges from 0.4% to 3%, while prevalence is higher in Eastern Europe and the Middle East and has reached 13% in Egypt. Many infected people do not know their status. In the United States, the infected population was estimated to decline from 3.15 million in 2005 to 2.47 million in 2021, even as the burden aged and mortality was expected to rise from 2.0% to 2.9%. Only about half of infections were diagnosed, and fewer than 4% of all infected people were treated in the cited assessment.

Transmission is predominantly parenteral. Before the 1990s, blood-product transfusion, intravenous drug use, and unsafe injections accounted for approximately 70% of cases in industrialized countries. Systematic screening transformed the transfusion risk, reducing it to roughly one infection per two million transfusions. Current routes include intravenous or nasal drug use, mother-to-child transmission, unsafe medical or surgical procedures, and occasional transmission through tattooing or acupuncture with contaminated materials. Heterosexual transmission is generally low, but the risk is higher among HIV-infected men who have sex with men. Around 30% of infections remain unexplained, leaving surveillance and prevention dependent on both recognized exposures and broader infection-control systems.

Hemodialysis created a particularly important environmental setting for transmission. In the early 1990s, patients receiving hemodialysis had high prevalence and incidence, and prevalence correlated with time on dialysis independently of transfusion burden. Infection was more common in hemodialysis than in peritoneal dialysis or home hemodialysis, and substantial prevalence occurred even among patients who had never been transfused. As blood safety improved and erythropoiesis-stimulating agents reduced the need for transfusion, attention shifted toward nosocomial transmission within dialysis units.

Molecular virology made that shift demonstrable. From the mid-1990s onward, phylogenetic analysis identified clusters of closely related HCV isolates among patients treated in the same hemodialysis units. Variable regions of the viral genome functioned as molecular fingerprints, allowing investigators to compare viral quasi-species and estimate whether infections probably came from a common source. In a systematic review of 20 studies, however, no single transmission route was conclusively established. Eighteen studies found that some or all newly infected patients did not share a dialysis machine with the source patient, and only one considered transmission through the machine’s internal fluid pathway possible. The machine circuit therefore appeared to play, at most, a small role; failures in infection-control procedures were the more probable explanation.

Systemic and Renal Disease

Hepatitis C virus infection is treated as a systemic disease because its effects are not confined to hepatic inflammation or fibrosis. It can induce autoimmune, dermatological, and renal disease, including cryoglobulinemia-associated vasculitis and glomerular lesions. Patients with HCV-associated glomerulonephritis are HCV RNA-positive in serum, and HCV seropositivity is markedly overrepresented among patients with membranoproliferative glomerulonephritis. Fabrizi and colleagues reported that the prevalence of HCV seropositivity in case series of membranoproliferative glomerulonephritis was approximately ten times the prevalence reported in HCV-negative patients.

Epidemiologic studies connect infection with both chronic kidney disease and its progression. In a United States study of 18,002 HCV-infected patients compared with 25,137 controls whose baseline estimated glomerular filtration rate exceeded 60 ml/min/1.73 m2, HCV infection was associated with a higher risk of developing stage 3–5 chronic kidney disease. Age, hypertension, diabetes, and decompensated liver disease also increased risk, but HCV-infected patients reached chronic kidney disease more quickly. In another comparison, chronic kidney disease affected 9.6% of anti-HCV-positive patients versus 5.1% of HCV-negative patients, with a higher baseline viral load independently predicting kidney disease.

The renal signal is not limited to reduced filtration. In the NHANES III analysis, HCV seropositivity was associated with albuminuria in an age-dependent manner: the adjusted odds ratio was 1.84 among people aged 40–59 years and 1.27 among those aged 60 years or older. Among the older HCV-positive group, 46% had albuminuria compared with 24% of antibody-negative individuals. A Taiwanese study likewise found proteinuria in 8.3% of anti-HCV-positive, non-diabetic patients compared with 5.1% of the seronegative group, with an adjusted odds ratio of 1.84. These findings show that HCV can leave a renal mark even when low estimated glomerular filtration is not yet evident.

Treatment and Prevention

By 2011, standard treatment combined pegylated interferon and ribavirin, with response shaped by viral genotype and early viral kinetics. Sustained virologic response represented complete virologic recovery and, in the absence of liver comorbidities, remodeling of fibrosis. The combination produced sustained virologic response in more than half of patients with chronic infection, but more than half of those with genotype 1 did not achieve it. That therapeutic limitation drove the development of direct-acting antiviral drugs aimed at viral enzymes, including genotype 1-specific NS3/NS4A protease inhibitors and NS5B polymerase inhibitors, as well as broader-spectrum NS5A or entry inhibitors and nonspecific agents such as new interferons and cyclophilin inhibitors.

The first-wave protease inhibitors telaprevir and boceprevir increased sustained virologic response rates in genotype 1 infection by approximately 20–30%. About 75% of previously untreated genotype 1 patients achieved sustained virologic response after 12 weeks of telaprevir-based triple therapy, with an overall 24-week course permitted for many patients who achieved extended rapid virologic response. Boceprevir-based therapy produced sustained virologic response in about 65% of comparable patients after a four-week lead-in with standard treatment followed by 24–44 weeks of triple therapy. Among treatment-experienced patients, triple therapy achieved approximately 85% response in previous relapsers, 55% in partial responders, and 30% in null responders. The new drugs nevertheless introduced concerns about rash, anemia, cost, adherence, resistance, and drug interactions.

Prevention in hemodialysis depends primarily on strict hygiene rather than on physically separating infected patients. Staff should wash hands before and after contact with a patient or dialysis equipment, use alcohol-based hand rub when hands are not visibly contaminated, wear disposable gloves while caring for patients or touching potentially contaminated surfaces, and remove gloves when leaving the dialysis station. Single-use items should be discarded after one patient, reusable items should be disinfected or dedicated to one patient, and dialysis-station surfaces should be cleaned after each session, with stronger disinfection for visible contamination. Regular observational audits and performance reviews reinforce these measures.

The KDIGO workgroup concluded that dedicated dialysis machines for HCV-infected patients were not recommended because the internal machine pathway appeared to have little role in transmission. Separate-ward isolation was also not recommended as a substitute for infection-control procedures: large observational studies, including the Dialysis Outcomes and Practice Patterns Study, found no independent protective effect after adjustment for confounding factors. Isolation may have heightened awareness in some settings, but careful practice at the point of care remained the central preventive intervention.

Kidney Transplantation and Long-Term Outcomes

Hepatitis C virus infection is the main cause of chronic liver disease in kidney transplant recipients and affects outcomes before, during, and after transplantation. Its prevalence among transplant candidates fell as infection declined in the dialysis population; a Spanish collaborative review found anti-HCV prevalence among kidney transplant patients falling from 29.5% in 1990 to 19% in 1994 and 10% in 1998. Even with this decline, infected recipients faced increased risks of proteinuria, glomerulonephritis, chronic rejection, transplant glomerulopathy, serious infection, new-onset diabetes after transplantation, liver disease, and extrahepatic neoplasia such as post-transplant lymphoproliferative disease.

The effect on acute rejection has been inconsistent. Some observations suggest that HCV-related immune alterations reduce rejection, including reductions in naive T-helper lymphocytes and altered lymphocyte proliferative responses. Other studies have not established a consistent protective or harmful effect. The more stable pattern concerns the accumulation of chronic complications: proteinuria may reflect chronic allograft nephropathy, transplant glomerulopathy, or HCV-associated glomerulonephritis, while new-onset diabetes and serious infections add independent burdens to both patient and graft survival.

Long-term survival is worse in anti-HCV-positive recipients than in uninfected recipients, particularly more than ten years after transplantation. A meta-analysis of eight clinical trials involving 6,365 patients found a relative risk of mortality of 1.79 for HCV infection, with part of the excess explained by liver-related death. HCV was also identified as an independent risk factor for graft loss, plausibly through the combined effects of new-onset diabetes, chronic rejection, transplant glomerulopathy, proteinuria, and HCV-related glomerulonephritis. In some series, anti-HCV antibodies were substantially more frequent among patients with transplant glomerulopathy, supporting a possible pathway involving direct or indirect endothelial injury and cytokine release.

Yet the infection does not reverse the central therapeutic conclusion for end-stage renal disease. Multiple studies found that HCV-infected patients who received a kidney transplant had lower mortality than comparable patients who remained on dialysis or on the waiting list. One report found a relative risk of death of 0.31 during the period seven to forty-eight months after transplantation. In another analysis of 175 HCV-infected transplant candidates, the hazard ratio for death was initially 2.51 during the first six months after transplantation but fell to 0.32 during months seven to eighty-four. Thus transplantation carries early hazards but ultimately preserves the survival advantage seen in end-stage renal disease generally.

Post-transplant care therefore requires active surveillance rather than therapeutic resignation. Immunosuppression may need adjustment, and outpatient follow-up should seek early evidence of proteinuria, allograft dysfunction, infection, new-onset diabetes, neoplasia, and worsening liver disease. The balance is exacting: immunosuppression can permit viral and hepatic progression, yet transplantation remains preferable to prolonged dialysis for many infected patients.

Knowledge, Uncertainty, and Significance

The history of hepatitis C virus infection is also a history of increasingly precise medical classification. Antibody testing established exposure; HCV RNA separated active infection from recovery; genotyping organized viral diversity; phylogenetic analysis exposed hidden transmission chains; and viral kinetics helped determine treatment duration. The progression from non-A, non-B hepatitis to molecularly defined infection converted an obscure clinical pattern into a condition that could be screened, mapped, treated, and managed within guidelines.

At the same time, the evidence retains important limits. Studies of transplant outcomes often classified infection by enzyme-linked immunosorbent assay rather than nucleic acid testing and did not systematically assess pretransplant liver histology. Research on HCV-positive donor kidneys lacked donor and recipient HCV RNA data, did not provide genotype information needed to assess superinfection, and did not systematically evaluate liver histology. These gaps matter because antibody status, active viremia, genotype matching, fibrosis, and histologic progression are not interchangeable variables.

The infection consequently occupies several clinical worlds at once: a silent population burden, a treatable viral disease, a cause of renal and hepatic injury, a preventable hazard in hemodialysis units, and a modifier of transplant survival. Its significance is not captured by liver disease alone. The decisive question is how accurately each patient’s viral state is defined, how reliably medical environments prevent transmission, and how deliberately clinicians balance antiviral benefit, immunosuppression, renal replacement, and the long horizon of graft and patient survival.